For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.
Adverse Events Module path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Groups
Study -> Results Section -> Adverse Events Module -> Serious Events
Study -> Results Section -> Adverse Events Module -> Other Events
| Title | Description | Deaths # Affected | Deaths # At Risk | Serious # Affected | Serious # At Risk | Other # Affected | Other # At Risk | View |
|---|---|---|---|---|---|---|---|---|
| Dose Level 1 | Capecitabine was given 825 mg/m\^2 twice/day during radiotherapy with drug holidays (weekend breaks). Temozolomide was given 45 mg/m\^2 once/day during radiotherapy with drug holidays (weekend breaks). | None | None | 0 | 2 | 2 | 2 | View |
| Dose Level 2 | Capecitabine was given 825 mg/m\^2 twice/day during radiotherapy with drug holidays (weekend breaks). Temozolomide was given 60 mg/m\^2 once/day during radiotherapy with drug holidays (weekend breaks). | None | None | 0 | 2 | 2 | 2 | View |
| Dose Level 3/Recommended Dose | Capecitabine was given 825 mg/m\^2 twice/day during radiotherapy with drug holidays (weekend breaks). Temozolomide was given 75 mg/m\^2 once/day during radiotherapy with drug holidays (weekend breaks). | None | None | 0 | 18 | 18 | 18 | View |
| Term | Type | Organ System | Vocab | View |
|---|---|---|---|---|
| Febrile neutropenia | SYSTEMATIC_ASSESSMENT | Blood and lymphatic system disorders | None | View |
| Leukopenia | SYSTEMATIC_ASSESSMENT | Blood and lymphatic system disorders | None | View |
| Neutropenia | SYSTEMATIC_ASSESSMENT | Blood and lymphatic system disorders | None | View |
| Thrombocytopenia | SYSTEMATIC_ASSESSMENT | Blood and lymphatic system disorders | None | View |
| Anorexia | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | None | View |
| Constipation | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | None | View |
| Diarrhea | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | None | View |
| Nausea | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | None | View |
| Vomiting | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | None | View |
| Fatigue | SYSTEMATIC_ASSESSMENT | General disorders | None | View |
| Hand-foot syndrome | SYSTEMATIC_ASSESSMENT | General disorders | None | View |
| ALT abnormalities | SYSTEMATIC_ASSESSMENT | Hepatobiliary disorders | None | View |
| AST abnormalities | SYSTEMATIC_ASSESSMENT | Hepatobiliary disorders | None | View |
| Anemia | SYSTEMATIC_ASSESSMENT | Blood and lymphatic system disorders | None | View |